Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa
Authors
Keywords
-
Journal
Nature Reviews Clinical Oncology
Volume 15, Issue 5, Pages 310-324
Publisher
Springer Nature
Online
2018-02-13
DOI
10.1038/nrclinonc.2018.9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and safety of atezolizumab (atezo) and bevacizumab (bev) in a phase Ib study of microsatellite instability (MSI)-high metastatic colorectal cancer (mCRC).
- (2017) Howard S. Hochster et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase II study of atezolizumab (atezo) with or without bevacizumab (bev) versus sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) patients (pts).
- (2017) David F. McDermott et al. JOURNAL OF CLINICAL ONCOLOGY
- Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study
- (2017) Andrea B. Apolo et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor-targeted delivery of sunitinib base enhances vaccine therapy for advanced melanoma by remodeling the tumor microenvironment
- (2017) Meirong Huo et al. JOURNAL OF CONTROLLED RELEASE
- Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
- (2017) Arjun V Balar et al. LANCET
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
- (2017) Arjun V Balar et al. LANCET ONCOLOGY
- Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming
- (2017) Lin Tian et al. NATURE
- Tumour ischaemia by interferon-γ resembles physiological blood vessel regression
- (2017) Thomas Kammertoens et al. NATURE
- T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
- (2017) Enfu Hui et al. SCIENCE
- Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade
- (2017) Martina Schmittnaegel et al. Science Translational Medicine
- Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation
- (2017) Elizabeth Allen et al. Science Translational Medicine
- Combined Anti-VEGF and Anti–CTLA-4 Therapy Elicits Humoral Immunity to Galectin-1 Which Is Associated with Favorable Clinical Outcomes
- (2017) Xinqi Wu et al. Cancer Immunology Research
- Tumor-Associated Lymphatic Vessels Upregulate PDL1 to Inhibit T-Cell Activation
- (2017) Lothar C. Dieterich et al. Frontiers in Immunology
- CTLA-4 and PD-1 Pathways
- (2016) Elizabeth I. Buchbinder et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Normalization of Tumor Vessels by Tie2 Activation and Ang2 Inhibition Enhances Drug Delivery and Produces a Favorable Tumor Microenvironment
- (2016) Jin-Sung Park et al. CANCER CELL
- Efficacy of Cotargeting Angiopoietin-2 and the VEGF Pathway in the Adjuvant Postsurgical Setting for Early Breast, Colorectal, and Renal Cancers
- (2016) Florence T.H. Wu et al. CANCER RESEARCH
- The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition
- (2016) P. S. Hegde et al. CLINICAL CANCER RESEARCH
- The hepatocyte growth factor (HGF)–MET receptor tyrosine kinase signaling pathway: Diverse roles in modulating immune cell functions
- (2016) Subburaj Ilangumaran et al. CYTOKINE
- Tertiary lymphoid structures, drivers of the anti-tumor responses in human cancers
- (2016) Marie-Caroline Dieu-Nosjean et al. IMMUNOLOGICAL REVIEWS
- VEGF Requires the Receptor NRP-1 To Inhibit Lipopolysaccharide-Dependent Dendritic Cell Maturation
- (2016) Nougboli A. E. Oussa et al. JOURNAL OF IMMUNOLOGY
- IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial
- (2016) Brian I Rini et al. LANCET ONCOLOGY
- Mechanisms and regulation of endothelial VEGF receptor signalling
- (2016) Michael Simons et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Targeted vaccination against the bevacizumab binding site on VEGF using 3D-structured peptides elicits efficient antitumor activity
- (2016) Madelon Q. Wentink et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages
- (2016) Teresa E. Peterson et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival
- (2016) Jonas Kloepper et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma
- (2016) Jeffrey J. Wallin et al. Nature Communications
- Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
- (2016) Shohei Koyama et al. Nature Communications
- Activation of the PD-1/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis
- (2016) Madison Black et al. Oncotarget
- VEGF Neutralization Plus CTLA-4 Blockade Alters Soluble and Cellular Factors Associated with Enhancing Lymphocyte Infiltration and Humoral Recognition in Melanoma
- (2016) X. Wu et al. Cancer Immunology Research
- Efficacy of PD-1 Blockade Is Potentiated by Metformin-Induced Reduction of Tumor Hypoxia
- (2016) Nicole E. Scharping et al. Cancer Immunology Research
- Myeloma Drug Resistance Induced by Binding of Myeloma B7-H1 (PD-L1) to PD-1
- (2016) M. Ishibashi et al. Cancer Immunology Research
- Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy
- (2016) Xinqi Wu et al. Cancer Immunology Research
- Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastoma
- (2015) A. Scholz et al. EMBO Molecular Medicine
- VEGF suppresses T-lymphocyte infiltration in the tumor microenvironment through inhibition of NF-κB-induced endothelial activation
- (2015) Hua Huang et al. FASEB JOURNAL
- Hepatocyte Growth Factor Receptor c-Met Instructs T Cell Cardiotropism and Promotes T Cell Migration to the Heart via Autocrine Chemokine Release
- (2015) Izabela Komarowska et al. IMMUNITY
- Novel Roles of c-Met in the Survival of Renal Cancer Cells through the Regulation of HO-1 and PD-L1 Expression
- (2015) Murugabaskar Balan et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future
- (2015) Lieping Chen et al. JOURNAL OF CLINICAL INVESTIGATION
- VEGF-A modulates expression of inhibitory checkpoints on CD8+T cells in tumors
- (2015) Thibault Voron et al. JOURNAL OF EXPERIMENTAL MEDICINE
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adoptive cell transfer as personalized immunotherapy for human cancer
- (2015) S. A. Rosenberg et al. SCIENCE
- PDGF upregulates CLEC-2 to induce T regulatory cells
- (2015) Sudhanshu Agrawal et al. Oncotarget
- Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma
- (2015) X.-D. Liu et al. Cancer Immunology Research
- Inhibition of the angiopoietin/Tie2 axis induces immunogenic modulation, which sensitizes human tumor cells to immune attack
- (2015) Italia Grenga et al. Journal for ImmunoTherapy of Cancer
- Robo4 vaccines induce antibodies that retard tumor growth
- (2014) Xiaodong Zhuang et al. ANGIOGENESIS
- The Role of Mechanical Forces in Tumor Growth and Therapy
- (2014) Rakesh K. Jain et al. Annual Review of Biomedical Engineering
- Postsurgical Adjuvant Tumor Therapy by Combining Anti-Angiopoietin-2 and Metronomic Chemotherapy Limits Metastatic Growth
- (2014) Kshitij Srivastava et al. CANCER CELL
- Restoration of natural killer cell cytotoxicity by VEGFR-3 inhibition in myelogenous leukemia
- (2014) Ji Yoon Lee et al. CANCER LETTERS
- Enhancement of T cell recruitment and infiltration into tumours
- (2014) C. Oelkrug et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Clever-1/Stabilin-1 Controls Cancer Growth and Metastasis
- (2014) M. Karikoski et al. CLINICAL CANCER RESEARCH
- Tumor endothelial marker 1–specific DNA vaccination targets tumor vasculature
- (2014) John G. Facciponte et al. JOURNAL OF CLINICAL INVESTIGATION
- Oxidative Stress Regulates Expression of VEGFR1 in Myeloid Cells: Link to Tumor-Induced Immune Suppression in Renal Cell Carcinoma
- (2014) S. Kusmartsev et al. JOURNAL OF IMMUNOLOGY
- IFNγ-responsiveness of endothelial cells leads to efficient angiostasis in tumours involving down-regulation of Dll4
- (2014) Jingjing Deng et al. JOURNAL OF PATHOLOGY
- Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine
- (2014) Anna R Kwilas et al. Journal of Translational Medicine
- Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors
- (2014) Gregory T Motz et al. NATURE MEDICINE
- Regulation of T cell proliferation by JMJD6 and PDGF-BB during chronic hepatitis B infection
- (2014) Cai-Feng Chen et al. Scientific Reports
- Pretreatment Serum VEGF Is Associated with Clinical Response and Overall Survival in Advanced Melanoma Patients Treated with Ipilimumab
- (2014) J. Yuan et al. Cancer Immunology Research
- Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
- (2014) F. S. Hodi et al. Cancer Immunology Research
- A Core Human Primary Tumor Angiogenesis Signature Identifies the Endothelial Orphan Receptor ELTD1 as a Key Regulator of Angiogenesis
- (2013) Massimo Masiero et al. CANCER CELL
- Bevacizumab-Induced Normalization of Blood Vessels in Tumors Hampers Antibody Uptake
- (2013) M. Arjaans et al. CANCER RESEARCH
- Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy
- (2013) Y. Huang et al. CANCER RESEARCH
- Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effectin vivo
- (2013) S. Yasuda et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- Combination of sunitinib with anti-tumor vaccination inhibits T cell priming and requires careful scheduling to achieve productive immunotherapy
- (2013) Ritika Jaini et al. INTERNATIONAL JOURNAL OF CANCER
- Bevacizumab reduces tumor targeting of antiepidermal growth factor and anti-insulin-like growth factor 1 receptor antibodies
- (2013) Sandra Heskamp et al. INTERNATIONAL JOURNAL OF CANCER
- Platelet-derived growth factor-BB accelerates prostate cancer growth by promoting the proliferation of mesenchymal stem cells
- (2013) Jiwen Cheng et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- The neurotrophic hepatocyte growth factor attenuates CD8+ cytotoxic T-lymphocyte activity
- (2013) Mahdia Benkhoucha et al. Journal of Neuroinflammation
- Defective Mismatch Repair and Benefit from Bevacizumab for Colon Cancer: Findings from NSABP C-08
- (2013) Kay Pogue-Geile et al. JNCI-Journal of the National Cancer Institute
- Tumor Necrosis Factor Alpha-Induced Hypoxia-Inducible Factor 1 - -Catenin Axis Regulates Major Histocompatibility Complex Class I Gene Activation through Chromatin Remodeling
- (2013) S. Ghosh et al. MOLECULAR AND CELLULAR BIOLOGY
- Combining Antiangiogenic Therapy with Adoptive Cell Immunotherapy Exerts Better Antitumor Effects in Non-Small Cell Lung Cancer Models
- (2013) Shujing Shi et al. PLoS One
- VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2
- (2012) N G Gavalas et al. BRITISH JOURNAL OF CANCER
- VEGFA-VEGFR Pathway Blockade Inhibits Tumor-Induced Regulatory T-cell Proliferation in Colorectal Cancer
- (2012) M. Terme et al. CANCER RESEARCH
- Suppression, subversion and escape: the role of regulatory T cells in cancer progression
- (2012) K. Oleinika et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Neuropilin 1 deficiency on CD4+Foxp3+regulatory T cells impairs mouse melanoma growth
- (2012) Wiebke Hansen et al. JOURNAL OF EXPERIMENTAL MEDICINE
- The HGF Receptor/Met Tyrosine Kinase Is a Key Regulator of Dendritic Cell Migration in Skin Immunity
- (2012) J.-H. Baek et al. JOURNAL OF IMMUNOLOGY
- Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy
- (2012) Y. Huang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The role of immunosuppression of mesenchymal stem cells in tissue repair and tumor growth
- (2012) Zhipeng Han et al. Cell and Bioscience
- A Novel Function for Programmed Death Ligand-1
- (2011) Yiping Jin et al. AMERICAN JOURNAL OF PATHOLOGY
- Angiopoietin-2 promotes myeloid cell infiltration in a 2-integrin-dependent manner
- (2011) A. Scholz et al. BLOOD
- Glioblastoma Recurrence after Cediranib Therapy in Patients: Lack of "Rebound" Revascularization as Mode of Escape
- (2011) E. di Tomaso et al. CANCER RESEARCH
- Human Solid Tumors Contain High Endothelial Venules: Association with T- and B-Lymphocyte Infiltration and Favorable Prognosis in Breast Cancer
- (2011) L. Martinet et al. CANCER RESEARCH
- Molecular Pathways: Hypoxia Response in Immune Cells Fighting or Promoting Cancer
- (2011) Asis Palazón et al. CLINICAL CANCER RESEARCH
- PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine
- (2011) M. A. Cheever et al. CLINICAL CANCER RESEARCH
- Specifically Targeting Angiopoietin-2 Inhibits Angiogenesis, Tie2-Expressing Monocyte Infiltration, and Tumor Growth
- (2011) H. Huang et al. CLINICAL CANCER RESEARCH
- Regression of established hepatocellular carcinoma is induced by chemoimmunotherapy in an orthotopic murine model
- (2011) Diego M. Avella et al. HEPATOLOGY
- Common Lymphatic Endothelial and Vascular Endothelial Receptor-1 Mediates the Transmigration of Regulatory T Cells across Human Hepatic Sinusoidal Endothelium
- (2011) Shishir Shetty et al. JOURNAL OF IMMUNOLOGY
- Angiopoietin 2 Stimulates TIE2-Expressing Monocytes To Suppress T Cell Activation and To Promote Regulatory T Cell Expansion
- (2011) Seth B. Coffelt et al. JOURNAL OF IMMUNOLOGY
- Human brain endothelial cells endeavor to immunoregulate CD8 T cells via PD-1 ligand expression in multiple sclerosis
- (2011) Camille L Pittet et al. Journal of Neuroinflammation
- Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells
- (2011) Andrea Facciabene et al. NATURE
- The PDL1-PD1 Axis Converts Human TH1 Cells into Regulatory T Cells
- (2011) S. Amarnath et al. Science Translational Medicine
- Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma
- (2010) Brian I. Rini et al. CANCER
- Active Immunotherapy Induces Antibody Responses That Target Tumor Angiogenesis
- (2010) J. Schoenfeld et al. CANCER RESEARCH
- HGF/c-Met Acts as an Alternative Angiogenic Pathway in Sunitinib-Resistant Tumors
- (2010) F. Shojaei et al. CANCER RESEARCH
- Angiopoietin-2 Regulates Gene Expression in TIE2-Expressing Monocytes and Augments Their Inherent Proangiogenic Functions
- (2010) S. B. Coffelt et al. CANCER RESEARCH
- Antiangiogenic Agents Can Increase Lymphocyte Infiltration into Tumor and Enhance the Effectiveness of Adoptive Immunotherapy of Cancer
- (2010) R. K. Shrimali et al. CANCER RESEARCH
- Different Tumor Microenvironments Contain Functionally Distinct Subsets of Macrophages Derived from Ly6C(high) Monocytes
- (2010) K. Movahedi et al. CANCER RESEARCH
- The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents
- (2010) Dietmar W. Siemann CANCER TREATMENT REVIEWS
- Vaccination against the extra domain-B of fibronectin as a novel tumor therapy
- (2010) Elisabeth J. M. Huijbers et al. FASEB JOURNAL
- Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination
- (2010) Anamika Bose et al. INTERNATIONAL JOURNAL OF CANCER
- Lymphoma endothelium preferentially expresses Tim-3 and facilitates the progression of lymphoma by mediating immune evasion
- (2010) Xiaoyuan Huang et al. JOURNAL OF EXPERIMENTAL MEDICINE
- c-Met and Its Ligand Hepatocyte Growth Factor/Scatter Factor Regulate Mature B Cell Survival in a Pathway Induced by CD74
- (2010) M. Gordin et al. JOURNAL OF IMMUNOLOGY
- A Decrease of Regulatory T Cells Correlates With Overall Survival After Sunitinib-based Antiangiogenic Therapy in Metastatic Renal Cancer Patients
- (2010) Olivier Adotevi et al. JOURNAL OF IMMUNOTHERAPY
- Hepatocyte growth factor inhibits CNS autoimmunity by inducing tolerogenic dendritic cells and CD25+Foxp3+ regulatory T cells
- (2010) M. Benkhoucha et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Contrasting Actions of Selective Inhibitors of Angiopoietin-1 and Angiopoietin-2 on the Normalization of Tumor Blood Vessels
- (2009) Beverly L. Falcón et al. AMERICAN JOURNAL OF PATHOLOGY
- Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes
- (2009) C Alfaro et al. BRITISH JOURNAL OF CANCER
- Host-Derived Angiopoietin-2 Affects Early Stages of Tumor Development and Vessel Maturation but Is Dispensable for Later Stages of Tumor Growth
- (2009) Patrick Nasarre et al. CANCER RESEARCH
- The Novel Role of Tyrosine Kinase Inhibitor in the Reversal of Immune Suppression and Modulation of Tumor Microenvironment for Immune-Based Cancer Therapies
- (2009) J. Ozao-Choy et al. CANCER RESEARCH
- Sunitinib Inhibition of Stat3 Induces Renal Cell Carcinoma Tumor Cell Apoptosis and Reduces Immunosuppressive Cells
- (2009) H. Xin et al. CANCER RESEARCH
- Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1
- (2009) Dong-Ming Kuang et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Responsiveness of Stromal Fibroblasts to IFN- Blocks Tumor Growth via Angiostasis
- (2009) Y. Lu et al. JOURNAL OF IMMUNOLOGY
- Control of vascular morphogenesis and homeostasis through the angiopoietin–Tie system
- (2009) Hellmut G. Augustin et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells
- (2008) T. Azuma et al. BLOOD
- Anti-angiogenesis: making the tumor vulnerable to the immune system
- (2008) Arjan W. Griffioen CANCER IMMUNOLOGY IMMUNOTHERAPY
- The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients
- (2008) Takuya Osada et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Myeloid-Derived Suppressor Cells Promote Cross-Tolerance in B-Cell Lymphoma by Expanding Regulatory T Cells
- (2008) P. Serafini et al. CANCER RESEARCH
- Vascular normalization in Rgs5-deficient tumours promotes immune destruction
- (2008) Juliana Hamzah et al. NATURE
- Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy
- (2007) Ronald J Buckanovich et al. NATURE MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started